Pancoast肿瘤:11年单中心经验。

Catarina Pereira Moita, Catarina Figueiredo, Zenito Cruz, Ana Rita Costa, João Maciel, João Santos Silva, João Eurico Reis, Paulo Calvinho
{"title":"Pancoast肿瘤:11年单中心经验。","authors":"Catarina Pereira Moita, Catarina Figueiredo, Zenito Cruz, Ana Rita Costa, João Maciel, João Santos Silva, João Eurico Reis, Paulo Calvinho","doi":"10.48729/pjctvs.438","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Pancoast tumors encompass any tumor located on the lung apex, extending into structures in the thoracic inlet and, often, leading to the characteristic clinical syndrome. The main goal of this study is to analyze the response to multimodal treatment and outcome of patients with Pancoast tumors.</p><p><strong>Materials and methods: </strong>We performed a retrospective cohort single center study of patients with superior sulcus nonsmall cell lung carcinomas who underwent surgery between January of 2011 and February of 2022.</p><p><strong>Results: </strong>A total of ten patients were considered, 80,0% were male with a mean age of 53,6 (±6,6) years. At diagnosis, two tumors were stage II and eight were stage III. Histopathology revealed eight were adenocarcinomas and two were sarcomatoid carcinomas. All patients underwent neoadjuvant treatment before surgery. Nine patients received lung lobectomy, with en bloc resection comprising, predominantly, the chest wall (80,0%) and brachial plexus (30,0%). In one patient, surgery was aborted. Surgical histopathology showed free surgical margins were achieved in eight patients (80,0%). Two patients achieved full tumoral remission (ypT0N0, 22,2%), two tumors were stage I (22,2%), two were stage II (22,2%), two were stage III (22,2%) and one tumor was stage IV (11,1%). Mean disease-free survival was 83,9 (CI95% 42,1-125,8) months. 3-month disease-free survival rate was 88,9% and 1-year and 5-year disease-free survival rates were 63,5%. After the first-year follow-up, there was no evidence of disease progression. Mean overall survival was 115,7 (CI95% 89,3-142,1) months. At 3-month, 1-year and 5-years, overall survival was 88,9%.</p><p><strong>Conclusion: </strong>Although considering the small sample of patients, the survival of Pancoast tumors in our institution exhibits a positive outcome, when compared to current literature, Significant improvements have been reported recently, in understanding the nature of Pancoast tumors, emphasizing the importance of a multidisciplinary approach but still, further research is required.</p>","PeriodicalId":74480,"journal":{"name":"Portuguese journal of cardiac thoracic and vascular surgery","volume":"31 3","pages":"39-46"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pancoast Tumors: 11-Year Single-Centre Experience.\",\"authors\":\"Catarina Pereira Moita, Catarina Figueiredo, Zenito Cruz, Ana Rita Costa, João Maciel, João Santos Silva, João Eurico Reis, Paulo Calvinho\",\"doi\":\"10.48729/pjctvs.438\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Pancoast tumors encompass any tumor located on the lung apex, extending into structures in the thoracic inlet and, often, leading to the characteristic clinical syndrome. The main goal of this study is to analyze the response to multimodal treatment and outcome of patients with Pancoast tumors.</p><p><strong>Materials and methods: </strong>We performed a retrospective cohort single center study of patients with superior sulcus nonsmall cell lung carcinomas who underwent surgery between January of 2011 and February of 2022.</p><p><strong>Results: </strong>A total of ten patients were considered, 80,0% were male with a mean age of 53,6 (±6,6) years. At diagnosis, two tumors were stage II and eight were stage III. Histopathology revealed eight were adenocarcinomas and two were sarcomatoid carcinomas. All patients underwent neoadjuvant treatment before surgery. Nine patients received lung lobectomy, with en bloc resection comprising, predominantly, the chest wall (80,0%) and brachial plexus (30,0%). In one patient, surgery was aborted. Surgical histopathology showed free surgical margins were achieved in eight patients (80,0%). Two patients achieved full tumoral remission (ypT0N0, 22,2%), two tumors were stage I (22,2%), two were stage II (22,2%), two were stage III (22,2%) and one tumor was stage IV (11,1%). Mean disease-free survival was 83,9 (CI95% 42,1-125,8) months. 3-month disease-free survival rate was 88,9% and 1-year and 5-year disease-free survival rates were 63,5%. After the first-year follow-up, there was no evidence of disease progression. Mean overall survival was 115,7 (CI95% 89,3-142,1) months. At 3-month, 1-year and 5-years, overall survival was 88,9%.</p><p><strong>Conclusion: </strong>Although considering the small sample of patients, the survival of Pancoast tumors in our institution exhibits a positive outcome, when compared to current literature, Significant improvements have been reported recently, in understanding the nature of Pancoast tumors, emphasizing the importance of a multidisciplinary approach but still, further research is required.</p>\",\"PeriodicalId\":74480,\"journal\":{\"name\":\"Portuguese journal of cardiac thoracic and vascular surgery\",\"volume\":\"31 3\",\"pages\":\"39-46\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Portuguese journal of cardiac thoracic and vascular surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.48729/pjctvs.438\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Portuguese journal of cardiac thoracic and vascular surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48729/pjctvs.438","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

简介:Pancoast肿瘤包括位于肺尖的任何肿瘤,延伸到胸入口处的结构,通常导致特征性的临床综合征。本研究的主要目的是分析Pancoast肿瘤患者对多模式治疗的反应和预后。材料和方法:我们对2011年1月至2022年2月期间接受手术的上沟非小细胞肺癌患者进行了回顾性队列单中心研究。结果:共纳入10例患者,其中男性占80%,平均年龄53,6(±6,6)岁。诊断时,2例肿瘤为II期,8例为III期。组织病理学显示8例为腺癌,2例为肉瘤样癌。所有患者术前均接受新辅助治疗。9例患者接受肺叶切除术,整体切除主要包括胸壁(80%)和臂丛(30.0%)。有一个病人的手术流产了。手术组织病理学显示,8例患者(80.0%)实现了游离手术切缘。2例患者达到肿瘤完全缓解(ypT0N0, 22.2%), 2例肿瘤为I期(22.2%),2例为II期(22.2%),2例为III期(22.2%),1例肿瘤为IV期(11.1%)。平均无病生存期为83,9个月(CI95%为42,1-125,8个月)。3个月无病生存率为88.9%,1年、5年无病生存率为63.5%。在第一年的随访后,没有疾病进展的证据。平均总生存期为115,7个月(CI95%为89,3-142,1)个月。3个月、1年和5年的总生存率为88.9%。结论:虽然考虑到患者的小样本,我们机构的Pancoast肿瘤的生存表现出积极的结果,但与目前的文献相比,最近有报道称,在了解Pancoast肿瘤的性质方面取得了重大进展,强调了多学科方法的重要性,但仍然需要进一步的研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pancoast Tumors: 11-Year Single-Centre Experience.

Introduction: Pancoast tumors encompass any tumor located on the lung apex, extending into structures in the thoracic inlet and, often, leading to the characteristic clinical syndrome. The main goal of this study is to analyze the response to multimodal treatment and outcome of patients with Pancoast tumors.

Materials and methods: We performed a retrospective cohort single center study of patients with superior sulcus nonsmall cell lung carcinomas who underwent surgery between January of 2011 and February of 2022.

Results: A total of ten patients were considered, 80,0% were male with a mean age of 53,6 (±6,6) years. At diagnosis, two tumors were stage II and eight were stage III. Histopathology revealed eight were adenocarcinomas and two were sarcomatoid carcinomas. All patients underwent neoadjuvant treatment before surgery. Nine patients received lung lobectomy, with en bloc resection comprising, predominantly, the chest wall (80,0%) and brachial plexus (30,0%). In one patient, surgery was aborted. Surgical histopathology showed free surgical margins were achieved in eight patients (80,0%). Two patients achieved full tumoral remission (ypT0N0, 22,2%), two tumors were stage I (22,2%), two were stage II (22,2%), two were stage III (22,2%) and one tumor was stage IV (11,1%). Mean disease-free survival was 83,9 (CI95% 42,1-125,8) months. 3-month disease-free survival rate was 88,9% and 1-year and 5-year disease-free survival rates were 63,5%. After the first-year follow-up, there was no evidence of disease progression. Mean overall survival was 115,7 (CI95% 89,3-142,1) months. At 3-month, 1-year and 5-years, overall survival was 88,9%.

Conclusion: Although considering the small sample of patients, the survival of Pancoast tumors in our institution exhibits a positive outcome, when compared to current literature, Significant improvements have been reported recently, in understanding the nature of Pancoast tumors, emphasizing the importance of a multidisciplinary approach but still, further research is required.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信